Stocktoria
Aurinia Pharmaceuticals Inc. AUPH
Aurinia Pharmaceuticals Inc. (AUPH) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $283.1M at a 101.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2025-12-03 | Leerink Partners | Market Perform (down) |
| 2025-11-07 | Jefferies | Buy (up) |
| 2025-11-05 | RBC Capital | Sector Perform (down) |
| 2025-08-01 | RBC Capital | Outperform (main) |
| 2024-09-16 | Cantor Fitzgerald | Overweight (reit) |
| 2024-09-09 | Cantor Fitzgerald | Overweight (reit) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.53 |
| Retained earnings / assets | -0.864 |
| EBIT / assets | 0.14 |
| Equity / liabilities | 3.414 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc. | 5/9 | 5.18 | 7.7 | +20.4% |
| XERS | Xeris Biopharma Holdings, Inc. | 7/9 | -2.99 | — | +43.7% |
| HROW | HARROW, INC. | 6/9 | 1.29 | — | +36.4% |
| RIGL | RIGEL PHARMACEUTICALS INC | 5/9 | 0.31 | 2 | +64.1% |
| IRWD | IRONWOOD PHARMACEUTICALS INC | 4/9 | -11.97 | 28.3 | -15.7% |
| EOLS | Evolus, Inc. | 2/9 | -8.65 | — | +11.6% |
| LGND | LIGAND PHARMACEUTICALS INC | 4/9 | 6.75 | 48.9 | +60.4% |
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
FAQ
Is AUPH financially healthy?
Aurinia Pharmaceuticals Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does AUPH pay a dividend?
No, Aurinia Pharmaceuticals Inc. does not currently pay a dividend.
How profitable is AUPH?
In FY2025, Aurinia Pharmaceuticals Inc. had a net margin of 101.5% and a return on equity of 49.4%.
What is AUPH's P/E ratio?
Aurinia Pharmaceuticals Inc.'s trailing price-to-earnings (P/E) ratio is about 7.7×, based on its latest annual earnings.
What is the analyst price target for AUPH?
The average Wall-Street price target for Aurinia Pharmaceuticals Inc. is $17.00, about 10.0% above the recent price, from 7 analysts.
Is AUPH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Aurinia Pharmaceuticals Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 7.7×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.